KIT and acute myeloid leukemia: As quizartinib is a more potent and selective second-generation FLT3 inhibitor than the first-generation FLT3 inhibitor midostaurin, which was approved for AML treatment in 2017, it can inhibit multiple class III RTKs, including the structurally similar FLT3 and c-KIT.